Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5299-5306

  Noordeen, Faseeha ^a,b   Vaillant, Andrew ^c   Jilbert, Allison R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF PERADENIYA   (Sri Lanka)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CPG OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; POLYMER; REP 2006; REP 2031; REP 2055; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DUCK; DUCK HEPATITIS B; DUCK HEPATITIS B VIRUS; IN VIVO STUDY; INFECTION PREVENTION; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; CPG ISLANDS; DRUG ADMINISTRATION SCHEDULE; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; HEPATITIS, VIRAL, ANIMAL; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84885942075     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01005-13     Document Type: Article

References (34)

1. Zoulim F, Saadi F, Buronfosse T, Abdul F, Cova L. 2008. Animal models for the study of infection, p 6.1-6.20. In Locarnini S, Lai CL (ed), Hepatitis B virus, vol 1. International Medical Press, London, United Kingdom.
2. Schultz U, Grgacic E, Nassal M. 2004. Duck hepatitis B virus: An invaluable model system for HBV infection. Adv. Virus Res. 63:1-70.
3. Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ. 1996. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: One virus DNA genome is infectious in neonatal ducks. Virology 226:338-345.
4. Jilbert AR, Botten JA, Miller DS, Bertram EM, Hall PM, Kotlarski J, Burrell CJ. 1998. Characterization of age-And dose-related outcomes of duck hepatitis B virus infection. Virology 244:273-282.
5. Foster WK, Miller DS, Scougall CA, Kotlarski I, Colonno RJ, Jilbert AR. 2005. Effect of antiviral treatment with entecavir on age-And dose-related outcomes of duck hepatitis B virus infection. J. Virol. 79:5819-5832.
6. Foster WK, Miller DS, Marion PL, Colonno RJ, Kotlarski I, Jilbert AR. 2003. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob. Agents Chemother. 47: 2624-2635.
7. Miller DS, Boyle D, Feng F, Reaiche GY, Kotlarski I, Colonno R, Jilbert AR. 2008. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. Virology 373:329-341.
8. Feng F, Boyle CQ, Qiao Q, Boyle D, Jilbert AR. 2010. The development of a persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with a DNA or recombinant fowlpoxvirus vaccines. Vaccine 28:7436-7443.
9. Thermet A, Buronfosse T, Werle-Lapostolle B, Chevallier M, Pradat P, Trepo C, Zoulim F, Cova L. 2008. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J. Gen. Virol. 89:1192-1201.
10. Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S. 1998. Longterm therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 42:2132-2137.
11. Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. 1998. Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob. Agents Chemother. 42:3130-3135.
12. Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, Olsen EA, Juteau JM, Caughey B. 2006. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50:1034-1044.
13. Lee AM, Rojek JM, Gundersen A, Stroher U, Juteau JM, Vaillant A, Kunz S. 2008. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372:107-117.
14. Vaillant A, Juteau JM, Lu H, Liu S, Lackman-Smith C, Ptak R, Jiang S. 2006. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 50:1393-1401.
15. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, Wiley DC. 1999. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 16:3-9.
16. Bernstein DI, Goyette N, Cardin R, Kern ER, Boivin G, Ireland J, Juteau JM, Vaillant A. 2008. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob. Agents Chemother. 52:2727-2733.
17. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau JM, Bernstein DI, Vaillant A. 2009. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virology J. 6:214. doi:10.1186/1743-422X-6-214.
18. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. 2009. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137:673-681.
19. Noordeen F, Vaillant A, Jilbert AR. 2013. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob. Agents Chemother. 57:5291-5298.
20. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. 2007. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35:460-468.
21. Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS. 2009. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77:910-919.
22. Iversen PL, Zhu S, Meyer S, Zon G. 1992. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 2:211-222.
23. Gao WY, Storm C, Egan W, Cheng YC. 1993. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol. Pharmacol. 43:45-50.
24. Temsamani J, Kubert M, Tang J, Padmapriya A, Agrawal S. 1994. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4:35-42.
25. Kanaori K, Yasumura A, Tajima K, Makino K. 2004. 1H NMR study on equilibrium between parallel G-quartet structures. Nucleic Acids Symp. Ser. (Oxf.) 48:233-234.
26. Kanehara H, Mizuguchi M, Tajima K, Kanaori K, Makino K. 1997. Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate. Biochemistry 36:1790-1797.
27. Manzini G, Yathindra N, Xodo LE. 1994. Evidence for intramolecularly folded i-DNA structures in biologically relevant CCC-repeat sequences. Nucleic Acids Res. 22:4634-4640.
28. Miller DS, Kotlarski I, Jilbert AR. 2006. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner. Virology 351:159-169.
29. Miller DS, Halpern M, Kotlarski I, Jilbert AR. 2006. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology 348:297-308.
30. Miller DS, Bertram EM, Scougall CA, Kotlarski I, Jilbert AR. 2004. Studying host immune responses against duck hepatitis B virus infection. Methods Mol. Med. 96:3-25.
31. Pugh JC, Di Q, Mason WS, Simmons H. 1995. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles. J. Virol. 69:4814-4822.
32. Triyatni M, Ey P, Tran T, Le Mire M, Qiao M, Burrell C, Jilbert A. 2001. Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses. J. Gen. Virol. 82:373-378.
33. Whal GM, Stern M, Stark GR. 1979. Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hydridization by using dextran sulfate. Proc. Natl. Acad. Sci. U. S. A. 76:3683-3687.
34. Krieg AM. 2000. Immune effects and mechanisms of action of CpG motifs. Vaccine 19:618-622.